Simon D, et al. - In patients with psoriatic arthritis (PsA), a chronic inflammatory joint disease related to psoriasis, researchers ascertained if the use of methotrexate (MTX) and biological disease-modifying anti-rheumatic drugs (bDMARDs) affects bone structure and biomechanical properties. For this cross-sectional study, 165 PsA patients were analyzed, 79 received no DMARDs, 86 received DMARDs, of them 52 bDMARDs (TNF, IL-17- or IL-12/23 inhibitors) and 34 MTX. According to findings, bDMARD-treated PsA patients benefit from higher bone mass and better bone strength than PsA patients receiving MTX or no DMARDs despite the longer duration of the disease. The concept of better control of PsA-related bone disease by bDMARDs was supported in this analysis.